Preview

Нервно-мышечные болезни

Расширенный поиск

Гены-кандидаты, участвующие в развитии антипсихотик-индуцированной тардивной дискинезии у пациентов с шизофренией

https://doi.org/10.17650/2222-8721-2020-10-3-10-26

Полный текст:

Аннотация

Введение. Лекарственно-индуцированная дискинезия – ятрогенная нежелательная побочная реакция со стороны экстрапирамидной системы, возникающая на фоне приема лекарственных средств, чаще всего антипсихотиков, у пациентов с шизофренией. В конце XX в. проводились исследования поиска генов-кандидатов и носительства однонуклеотидных вариантов антипсихотик-индуцированной тардивной дискинезии.
Цель исследования – проанализировать результаты исследований, описывающих гены-кандидаты и их однонуклеотидные варианты, ассоциированные с антипсихотик-индуцированной тардивной дискинезией.
Материалы и методы. Проведен поиск полнотекстовых публикаций на русском и английском языках в базах данных eLIBRARY, PubMed, Web of Science, Springer с использованием ключевых слов (тардивная дискинезия, лекарственно-индуцированная тардивная дискинезия, антипсихотики, нейролептики, типичные антипсихотики, атипичные антипсихотики, гены, полиморфизмы) и комбинированные поиски слов за последнее 10-летие.
Результаты. В обзоре рассмотрены гены-кандидаты, кодирующие белки/ферменты, участвующие в фармакодинамике и фармакокинетике антипсихотиков.
Заключение. Своевременное выявление генетических особенностей пациента может способствовать разработке диагностических тест-систем и в дальнейшем подбору максимально безопасной и эффективной антипсихотической терапии.

Об авторах

Е. Э. Вайман
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России
Россия
192019 Санкт-Петербург, ул. Бехтерева, 3


Н. А. Шнайдер
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России
Россия
192019 Санкт-Петербург, ул. Бехтерева, 3


Н. Г. Незнанов
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России
Россия
192019 Санкт-Петербург, ул. Бехтерева, 3


Р. Ф. Насырова
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России
Россия

Регина Фаритовна Насырова  

192019 Санкт-Петербург, ул. Бехтерева, 3



Список литературы

1. Avinun R., Nevo A., Radtke S.R. et al. Divergence of an association between depressive symptoms and a dopamine polygenic score in Caucasians and Asians. Eur Arch Psychiatry Clin Neurosci 2019;270:229–35. DOI: 10.1007/s00406-019-01040-x. PMID: 31289926.

2. Lanning R.K., Zai C.C., Müller D.J. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics 2016;17(12):1339–51. DOI: 10.2217/pgs.16.26. PMID: 27469238.

3. Koning J.P., Vehof J., Burger H. et al. Genetic Risk and Outcome in Psychosis (GROUP) investigators. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl) 2012;219(3):727–36. DOI: 10.1007/s00213-011-2394-1. PMID: 21750899.

4. Müller D.J., Zai C.C., Sicard M. et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychoticinduced weight gain. Pharmacogenomics J 2012;12(2):156–64. DOI: 10.1038/tpj.2010.65. PMID: 20714340.

5. Zai C.C., Maes M.S., Tiwari A.K. et al. Genetics of tardive dyskinesia: Promising leads and ways forward. J Neurol Sci 2018;389:28–34. DOI: 10.1016/j.jns.2018.02.011. PMID: 29502799.

6. Funahashi Y., Yoshino Y., Yamazaki K. et al. Analysis of methylation and -141C Ins/Del polymorphisms of the dopamine receptor D2 gene in patients with schizophrenia. Psychiatry Res 2019;278:135–40. DOI: 10.1016/j.psychres.2019.06.001. PMID: 31176829.

7. Zai C.C., Tiwari A.K., De Luca V. et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009;19(5):317–28. DOI: 10.1016/j.euroneuro.2009.01.001. PMID: 19217756.

8. Fan C.H., Li L.H., Fu Y. et al. An association study on catechol O-methyltransferase gene polymorphism and tardive dyskinesia. Chin J Behavioral Med Sci (Chinese) 2007;16:16–7.

9. Zai C.C., Tiwari A.K., Müller D.J. et al. The catechol-O-methyl-transferase gene in tardive dyskinesia. World J Biol Psychiatry 2010;11(6):803–12. DOI: 10.3109/15622975.2010.486043. PMID: 20586531.

10. Novak G., Gallo A., Zai C.C. et al. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatr Genet 2010;20(1):39–43. DOI: 10.1097/YPG.0b013e3283351221. PMID: 20010315.

11. Basile V.S., Ozdemir V., Masellis M. et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001;6(2):230–4. DOI: 10.1038/sj.mp.4000847. PMID: 11317228.

12. Segman R.H., Heresco-Levy U., Finkel B. et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000;152:408–13. DOI: 10.1007/s002130000521. PMID: 11140333.

13. Bakker P.R., Al Hadithy A.F., Amin N. et al. Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study. PLoS One 2012;7(12): e50970. DOI: 10.1371/journal.pone.0050970. PMID: 23226551.

14. Son W.Y., Lee H.J., Yoon H.K. et al. GABA transporter SLC6A11 gene polymorphism associated with tardive dyskinesia. Nord J Psychiatry 2014;68:123–8. DOI: 10.3109/08039488.2013.780260. PMID: 23795861.

15. Ivanova S., Loonen A., Pechlivanoglou P. et al. NMDA receptor genotypes associated with the vulerability to develop dyskinesia. Transl Psychiatry 2012;2:e67. DOI: 10.1038/tp.2011.66. PMID: 22832729.

16. Fedorenko O.Y., Loonen A.J., Lang F. et al. Association study indicates a protective role of phosphatidylinositol4- phosphate-5-kinase against tardive dyskinesia. Int J Neuropsychopharmacol 2014;18(6):pii:pyu098. DOI: 10.1093/ijnp/pyu098. PMID: 25548108.

17. John J., Bhatia T., Kukshal P. et al. Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition. Schizophr Res 2016;174(1–3):29–34. DOI: 10.1016/j.schres.2016.03.031. PMID: 25548108.

18. Yu L., Yang M.S., Zhao J. et al. An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr Res 2004;71:179–83. DOI: 10.1016/j.schres.2004.01.001. PMID: 15374585.

19. He G., Zhang J., Li X.W. et al. Interleukin-10 -1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study. Neurosci Lett 2006;394:1–4. DOI: 10.1016/j.neulet.2005.06.054.

20. Zai C.C., Lee F.H., Tiwari A.K. et al. Investigation of the HSPG2 gene in tardive dyskinesia – new data and meta-analysis. Front Pharmacol 2018;9:974. DOI: 10.3389/fphar.2018.00974. PMID: 30283332.

21. MacNeil R.R., Müller D.J. Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry 2016;2(2):61–78. DOI: 10.1159/000445802. PMID: 27606321.

22. Tanaka S., Syu A., Ishiguro H. et al. DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. Pharmacogenomics J 2013;13(1):27–34. DOI: 10.1038/tpj.2011.36.

23. Tiwari A.K., Zai C.C., Likhodi O. et al. Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J 2012;12(3):260–6. DOI: 10.1038/tpj.2010.93. PMID: 21266946.

24. Liou Y.J., Wang Y.C., Chen J.Y. et al. The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia. Eur J Neurol 2008;15(12):1406–8. DOI: 10.1111/j.1468-1331.2008.02316.x. PMID: 19049562.

25. Saiz P.A., Susce M.T., Clark D.A. et al. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol 2008;23(2):107–14. DOI: 10.1002/hup.903. PMID: 17972277.

26. Boiko A.S., Ivanova S.A., Pozhidaev I.V. et al. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors. World J Biol Psychiatry 2019;9:1–6. DOI: 10.1080/15622975.2018.1548780. PMID: 30623717.

27. Lu J.Y., Tiwari A.K., Zai G.C. et al. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. Neurosci Lett 2018;686:17–22. DOI: 10.1016/j.neulet.2018.08.007. PMID: 30118782.

28. Naumovska Z., Nestorovska A.K., Filipce A. et al. Pharmacogenetics and antipsychotic treatment response. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2015;36(1):53–67. DOI: 10.1515/prilozi-2015-0030. PMID: 26076775.

29. Wang F., Fan H., Sun H. et al. Association between TNF-a promoter-308A/G polymoprhism and tardive dyskinesia in Chinese Han patients with schizophrenia. Prog NeuroPsychopharmacol Biol Psychiatry 2012;37:106–10. DOI: 10.1016/j.pnpbp.2011.12.007. PMID: 22227290.

30. Hori H., Ohmori O., Shinkai T. et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000;23:170–7. DOI: 10.1016/S0893-133X(99)00156-6. PMID: 10882843.

31. Pae C.U., Yu H.S., Kim J.J. et al. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol 2004;7(4):495–500. DOI: 10.1017/S1461145704004419. PMID: 15151706.

32. Chang F.C., Fung V.S. Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. Pharmgenomics Pers Med 2014;7:317–28. DOI: 10.2147/PGPM.S52806. PMID: 15151706.

33. Kampman O., Anttila S., Illi A. et al. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 2004;15:2517–20. DOI: 10.1097/00001756-200411150-00017. PMID: 15538186.

34. Zai C.C., Tiwari A.K., Chowdhury N.I. et al. Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. World J Biol Psychiatry 2019;20(1):91–5. DOI: 10.1080/15622975.2017.1301681. PMID: 28394697.

35. Zai C.C., Tiwari A.K., Mazzoco M. et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 2013;47(11):1760–5. DOI: 10.1016/j.jpsychires.2013.07.025. PMID: 24018103.

36. Souza R.P., de Luca V., Remington G. et al. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology (Berl) 2010;210(3):347–54. DOI: 10.1007/s00213-010-1829-4. PMID: 20369355.

37. Liou Y.J., Chen M.L., Wang Y.C. et al. Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 20095;150B(2):239–42. DOI: 10.1002/ajmg.b.30796. PMID: 18548510.

38. Ivanova S.A., Toshchakova V.A., Filipenko M.L. et al. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. World J Biol Psychiatry 2015;16(3):200–5. DOI: 10.3109/15622975.2014.995222. PMID: 25602162.

39. Lv Z., Rong B., Tong X. et al. The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk. Int J Neurosci 2016;126(11):1044–50. DOI: 10.3109/00207454.2015.1089504. PMID: 26398367.

40. Quartu M., Serra M.P., Boi M. et al. Tissue distribution of Ret, GFRalpha-1, GFRalpha-2 and GFRalpha-3 receptors in the human brainstem at fetal, neonatal and adult age. Brain Res 2007;1173:36–52. DOI: 10.1016/j.brainres.2007.07.064. PMID: 17825269.

41. Serra M.P., Quartu M., Mascia F. et al. Ret, GFRalpha-1, GFRalpha-2 and GFRalpha-3 receptors in the human hippocampus and fascia dentata. Int J Dev Neurosci 2005;23(5):425–38. DOI: 10.1016/j.ijdevneu.2005.05.003. PMID: 16002253.

42. Blackwood D.H., Fordyce A., Walker M.T. et al. Schizophrenia and affective disorders–cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001;69:428–33. DOI: 10.1086/321969. PMID: 11443544

43. Levesque D., Rouillard C. Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci 2007;30:22–30. DOI: 10.1016/j.tins.2006.11.006. PMID: 17134767.

44. Le Foll B., Gallo A., Le Strat Y. et al. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol 2009;2:1–17. DOI: 10.1097/FBP.0b013e3283242f05. PMID: 19179847.

45. Zetterstrom R.H., Solomin L., Jansson L. et al. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997;276:248–50. DOI: 10.1126/science.276.5310.248. PMID: 9092472.

46. Millar J.K., Mackie S., Clapcote S.J. et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol 2007;584:401–5. DOI: 10.1113/jphysiol.2007.140210. PMID: 17823207

47. Maheux J., Ethier I., Rouillard C. et al. Induction patterns of transcription factors of the nur family (nurr1, nur77, and nor- 1) by typical and atypical antipsychotics in the mouse brain: implication for their mechanism of action. J Pharmacol Exp Ther 2005;313:460–73. DOI: 10.1124/jpet.104.080184. PMID: 15615863.

48. Al Hadithy A.F., Ivanova S.A., Pechlivanoglou P. et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33: 475–81. DOI: 10.1016/j.pnpbp.2009. 01.010. PMID: 19439249.

49. Wilffert B., Al Hadithy A.F., Sing V.J. et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009;23:652–9. DOI: 10.1177/0269881108091594. PMID: 18562401.

50. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008;9:437–52. DOI: 10.1038/nrn2392. PMID: 18478032.

51. Hahn C.G., Wang H.Y., Cho D.S. et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006;12:824–8. DOI: 10.1038/nm1418. PMID: 18478032.

52. Kato T., Abe Y., Sotoyama H. et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry 2011;16:307–20. DOI: 10.1038/mp.2010.10. PMID: 20142818.

53. Karbownik M.S., Szemraj J., Wieteska L. et al. Antipsychotic drugs differentially affect mRNA expression of genes encodin g the neuregulin 1-downstream ErbB4- PI3K Pathway. Pharmacology 2016;98:4–12. DOI: 10.1159/000444534. PMID: 26960157.

54. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996;19:1–17. DOI: 10.1016/0920-9964(95)00049-6. PMID: 8888121.

55. Lai I.C., Chen M.L., Wang Y.C. et al. Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia. World J Biol Psychiatry 2011;12:143–8. DOI: 10.3109/15622975.2010.496870. PMID: 20726823.

56. Sun H., Wang F., Fan H. et al. The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenia patients. PLoS ONE 2013;8:e70963. DOI: 10.1371/journal.pone.0070963. PMID: 23951054.

57. Boskovic M., Vovk T., Saje M. et al. Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia. Neurochem Res 2013;38:433–42. DOI: 10.1007/s11064-012-0937-4. PMID: 23212700.

58. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009;156:1029–40. DOI: 10.1111/j.1476-5381.2008.00088.x. PMID: 19220290.

59. Tiwari A., Zai C., Likhodi O. et al. Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J 2012;12: 260–6. DOI: 10.1038/tpj.2010.93. PMID: 21266946.

60. Aberg K., Adkins D.E., Bukszár J. et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010;67(3):279–82. DOI: 10.1016/j.biopsych.2009.08.036. PMID: 19875103.

61. Greenbaum L., Alkelai A., Rigbi A. et al. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 2010;25(16):2809–17. DOI: 10.1002/mds.23377. PMID: 20939080.

62. Syu A., Ishiguro H., Inada T. et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010;35(5): 1155–64. DOI: 10.1038/npp.2009.220. PMID: 20072119.

63. Stum M., Girard E., Bangratz M. et al. Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz-Jampel syndrome neuromyotonia. Hum Mol Genet 2008;17(20):3166–79. DOI: 10.1093/hmg/ddn213. PMID: 18647752.

64. Franco I., Johansson A., Olsson K. et al. Somatic mutagenesis in satellite cells associates with human skeletal muscle aging. Nat Commun 2018;9(1):800. DOI: 10.1038/s41467-018-03244-6. PMID: 29476074.

65. Singhal N., Martin P.T. Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. Dev Neurobiol 2011; 71(11):982–1005. DOI: 10.1002/dneu.20953. PMID: 21766463.

66. Bordia T., Zhang D., Perez X.A. et al. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia. Exp Neurol 2016;286:32–9. DOI: 10.1016/j.expneurol.2016.09.009. PMID: 27658674.

67. Ivanova S.A., Al Hadithy A.F.Y., Brazovskaya N. et al. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol 2012;27:334–447. DOI: 10.1002/hup.2226.

68. Shinkai T., De Luca V., Utsunomiya K. et al. Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia. Neuromolecular Med 2008;10(4):362–7. DOI: 10.1007/s12017-008-8041-2. PMID: 18543120.

69. Xing Q., Gao R., Li H. et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006;7(7): 987–93. DOI: 10.2217/14622416.7.7.987. PMID: 17054409.

70. Suzuki Y., Tsuneyama N., Sugai T. et al. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia. J Clin Pharmacol 2013;33(3):411–4. DOI: 10.1097/JCP.0b013e31828ecd52. PMID: 23609388.

71. Solmi M., Pigato G., Kane J.M. et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci 2018;389:21–7. DOI: 10.1016/j.jns.2018.02.012. PMID: 29439776.

72. Thongket P., Pleansiri C., Thurakitwannakarn W. et al. Association of cholinergic muscarinic 2 receptor gene polymorphisms with learning aptitude among medical and fine arts students. J Med Assoc Thai 2016;99:S201–5. PMID: 29906045.

73. Lim S.A., Kang U.J., McGehee D.S. Striatal cholinergic interneuron regulation and circuit effects. Front Synaptic Neurosci 2014;6:22. DOI: 10.3389/fnsyn.2014.00022. PMID: 25374536.

74. Goldberg J.A., Ding J.B., Surmeier D.J. Muscarinic modulation of striatal function and circuitry. Handb Exp Pharmacol 2012;208:223–41. DOI: 10.1007/978-3-642-23274-9_10. PMID: 22222701.

75. Scarr E., Um J.Y., Cowie T.F. et al. Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia. Schizophr Res 2013;146:279–84. DOI: 10.1016/j.schres.2013.01.023. PMID: 23490763.

76. Porteous D.J., Millar J.K., Brandon N.J. et al. DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med 2011;17:699–706. DOI: 10.1016/j.molmed.2011.09.002. PMID: 22015021.

77. Su P., Li S., Chen S. et al. A dopamine D2 receptor-DISC1 protein complex may contribute to antipsychotic-like effects. Neuron 2014;84:1302–16. DOI: 10.1016/j.neuron.2014.11.007. PMID: 25433637.

78. Tanaka M., Ishizuka K., Nekooki-Machida Y. et al. Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington’s disease. J Clin Invest 2017;127:1438–50. DOI: 10.1172/JCI85594. PMID: 28263187.

79. Lipina T.V., Wang M., Liu F. et al. Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice. Neuropharmacology 2012;62:1252–62. DOI: 10.1016/j.neuropharm.2011.02.020. PMID: 21376063.

80. Sasaki H., Hashimoto K., Maeda Y. et al. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci 1995;56:Pl443–7. DOI: 10.1016/0024-3205(95)00218-u. PMID: 7791505.

81. Ivanova S.A., Geers L.M., Al Hadithy A.F.Y. et al. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 2014;50:172–7. DOI: 10.1016/j.pnpbp.2013.12.015. PMID: 24389397.

82. Ivanova S.A., Filipenko M.L., Vyalova N.M. et al. CYP1A2 and CYP2D6 Gene polymorphisms in schizophrenic patients with neuroleptic drug-induced side effects. Bull Exp Biol Med 2016;160(5):687–90. DOI: 10.1007/s10517-016-3250-4. PMID: 27021090.

83. Tiwari A.K., Deshpande S.N., Rao A.R. et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005;75(1):21–6. DOI: 10.1016/j.schres.2004.12.011. PMID: 15820320.


Для цитирования:


Вайман Е.Э., Шнайдер Н.А., Незнанов Н.Г., Насырова Р.Ф. Гены-кандидаты, участвующие в развитии антипсихотик-индуцированной тардивной дискинезии у пациентов с шизофренией. Нервно-мышечные болезни. 2020;10(3):10-26. https://doi.org/10.17650/2222-8721-2020-10-3-10-26

For citation:


Vaiman E.E., Shnayder N.A., Neznanov N.G., Nasyrova R.F. Candidate genes involved in the development of antipsychotic-induced tardive dyskinesia in patients with schizophrenia. Neuromuscular Diseases. 2020;10(3):10-26. (In Russ.) https://doi.org/10.17650/2222-8721-2020-10-3-10-26

Просмотров: 160


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2222-8721 (Print)
ISSN 2413-0443 (Online)